MedTrace Logo

A Phase II Window of Opportunity Trial of PRMT5 Inhibitor, GSK3326595, in Early Stage Breast Cancer

NCT04676516 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2022-10-25

No results posted yet for this study

Summary

This is a Phase II Randomized Window of Opportunity Trial Evaluating Clinical and Biological effects of PRMT5 inhibitor, GSK3326595, in Early Stage Breast Cancer

Conditions

Interventions

DRUG

GSK3326595

GSK3326595 is a first-in-class small molecule PRMT5 inhibitor in form of an oral capsule.

Sponsors & Collaborators

  • Ontario Institute for Cancer Research

    collaborator OTHER

  • GlaxoSmithKline

    collaborator INDUSTRY

  • London Regional Cancer Program, Canada

    collaborator OTHER

  • Hamilton Health Sciences Corporation

    collaborator OTHER

  • Ottawa Hospital Research Institute

    lead OTHER

Principal Investigators

  • John F. Hilton, MD · The Ottawa Hospital Cancer Centre

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-08
Primary Completion
2022-08-15
Completion
2022-08-15

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04676516 on ClinicalTrials.gov